Photo taken from Paul Moore/LinkedIn
Aug 23, 2024, 16:19
How ADCs are redefining cancer treatment – Zymeworks Inc.
Zymeworks Inc. shared a post on LinkedIn:
“Ongoing innovations in antibody-drug conjugates (ADCs) are revolutionizing cancer treatment.
Breakthroughs in linker-payload technologies and personalized medicine are enhancing therapeutic benefit and enabling treatments tailored to individual patients, providing new hope across various malignancies.
Explore how advancements in ADCs are redefining cancer treatment and our unique approach to their design and development in this article from Drug Target Review.”
Authors: Paul Moore, Raffaele Colombo and Jamie Rich
Source: Zymeworks Inc./LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12